[HTML][HTML] Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012
M Hussain, S Daignault-Newton… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
M Hussain, S Daignault-Newton, PW Twardowski, C Albany, MN Stein, LP Kunju, J Siddiqui…
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.govTargeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate
Cancer: Results From NCI 9012 - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC6075827 Other Formats PDF (1.0M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin …
Cancer: Results From NCI 9012 - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC6075827 Other Formats PDF (1.0M) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin …
Abstract
Purpose
To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response.
ncbi.nlm.nih.gov